Table 2 Changes in the incidence of CIPN and duration of chemotherapy

Incidence of PN, n (%)

Events

Events

Total

694

(27.2)

362

(28.4)

0.443

 Male

357

(26.5)

162

(24.0)

0.257

 Female

337

(28.0)

200

(33.2)

0.025

Anticancer medicine

Oxaliplatin

258

(23.3)

131

(23.7)

0.902

 Male

191

(24.8)

91

(23.6)

0.716

 Female

67

(19.9)

40

(23.8)

0.355

Paclitaxel

312

(32.4)

166

(34.5)

0.441

 Male

70

(32.1)

25

(22.9)

0.094

 Female

242

(32.5)

141

(37.9)

0.082

nab-Paclitaxel

124

(25.7)

65

(26.9)

0.720

 Male

96

(26.6)

46

(25.5)

0.836

 Female

28

(22.9)

19

(31.1)

0.282

Principal cancer

Stomach

4

(25.0)

0

(0)

0.541

Colorectum

23

(21.9)

11

(20.0)

0.841

Pancreas

19

(20.0)

23

(44.2)

0.002

Ovary

58

(34.5)

34

(36.1)

0.789

Lung

55

(25.9)

28

(23.3)

0.692

Uterus

50

(30.4)

35

(37.2)

0.274

Breast

29

(31.1)

15

(29.4)

0.852

Others

399

(27.8)

191

(28.4)

0.795

Unknown

57

(21.7)

25

(19.0)

0.599

Duration of treatment days

Total

164.90

163.60

0.862

 Male

173.19

165.91

0.465

 Female

155.63

161.12

0.599

Anticancer medicine

Oxaliplatin

183.79

161.93

0.054

 Male

196.07

169.22

0.058

 Female

155.71

145.25

0.568

Paclitaxel

145.41

154.14

0.426

 Male

114.76

119.27

0.802

 Female

154.39

164.36

0.448

nab-Paclitaxel

160.57

186.58

0.128

 Male

159.76

187.07

0.136

 Female

162.97

185.11

0.586

Principal cancer

Stomach

99.25

131.17

0.693

Colorectum

213.18

186.16

0.536

Pancreas

227.99

230.67

0.960

Ovary

166.34

158.72

0.768

Lung

171.55

150.81

0.340

Uterus

159.62

152.91

0.781

Breast

141.95

132.53

0.807

Others

165.24

171.41

0.540

Unknown

129.99

124.44

0.695